How can ABCA1 modulators achieve brain selectivity to avoid peripheral cholesterol dysregulation and hepatotoxicity?

drug-development open composite 71%
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
71%
Novelty
80%
Mechanistic
—
Druggability
—
Priority
78%
Importance
90%
Tractability
75%
Market price
50%

Description

While ABCA1 activation shows promise, the debate highlighted safety concerns from LXR agonist failures. The molecular basis for achieving CNS-selective ABCA1 modulation without systemic lipid disruption remains unresolved.

Source: Debate session sess_SDA-2026-04-04-frontier-lipidomics-dcdbc360 (Analysis: SDA-2026-04-04-frontier-lipidomics-dcdbc360)